These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36520422)

  • 1. External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups.
    Timmerman S; Valentin L; Ceusters J; Testa AC; Landolfo C; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Kaijser J; Scambia G; Andreotti R; Timmerman D; Bourne T; Van Calster B; Froyman W
    JAMA Oncol; 2023 Feb; 9(2):225-233. PubMed ID: 36520422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
    Hiett AK; Sonek JD; Guy M; Reid TJ
    Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
    Yoeli-Bik R; Longman RE; Wroblewski K; Weigert M; Abramowicz JS; Lengyel E
    JAMA Netw Open; 2023 Jul; 6(7):e2323289. PubMed ID: 37440228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort.
    Landolfo C; Bourne T; Froyman W; Van Calster B; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerova D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Timmerman D; Valentin L
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):231-242. PubMed ID: 36178788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Validation of O-RADS US Risk Stratification and Management System.
    Hack K; Gandhi N; Bouchard-Fortier G; Chawla TP; Ferguson SE; Li S; Kahn D; Tyrrell PN; Glanc P
    Radiology; 2022 Jul; 304(1):114-120. PubMed ID: 35438559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee.
    Andreotti RF; Timmerman D; Strachowski LM; Froyman W; Benacerraf BR; Bennett GL; Bourne T; Brown DL; Coleman BG; Frates MC; Goldstein SR; Hamper UM; Horrow MM; Hernanz-Schulman M; Reinhold C; Rose SL; Whitcomb BP; Wolfman WL; Glanc P
    Radiology; 2020 Jan; 294(1):168-185. PubMed ID: 31687921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses.
    Basha MAA; Metwally MI; Gamil SA; Khater HM; Aly SA; El Sammak AA; Zaitoun MMA; Khattab EM; Azmy TM; Alayouty NA; Mohey N; Almassry HN; Yousef HY; Ibrahim SA; Mohamed EA; Mohamed AEM; Afifi AHM; Harb OA; Algazzar HY
    Eur Radiol; 2021 Feb; 31(2):674-684. PubMed ID: 32809166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
    Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN
    J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
    Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
    Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates.
    Rizzo S; Cozzi A; Dolciami M; Del Grande F; Scarano AL; Papadia A; Gui B; Gandolfo N; Catalano C; Manganaro L
    Radiology; 2023 Apr; 307(1):e220795. PubMed ID: 36413127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Meta-Analysis of O-RADS Ultrasound and O-RADS MRI for Risk Assessment of Ovarian and Adnexal Lesions.
    Zhang Q; Dai X; Li W
    AJR Am J Roentgenol; 2023 Jul; 221(1):21-33. PubMed ID: 36722758
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Cao L; Wei M; Liu Y; Fu J; Zhang H; Huang J; Pei X; Zhou J
    Gynecol Oncol; 2021 Jul; 162(1):107-112. PubMed ID: 33966893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
    Pascual MA; Vancraeynest L; Timmerman S; Ceusters J; Ledger A; Graupera B; Rodriguez I; Valero B; Landolfo C; Testa AC; Bourne T; Timmerman D; Valentin L; Van Calster B; Froyman W
    Ultrasound Obstet Gynecol; 2024 Sep; 64(3):395-404. PubMed ID: 38477179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of American College of Radiology Ovarian-Adnexal Reporting and Data System ultrasound to predict malignancy risk in adnexal lesions.
    Li Y; Shao G; Wu M; Zhang F; Zhang Y; Shao C
    J Obstet Gynaecol Res; 2024 Feb; 50(2):225-232. PubMed ID: 37990446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of adnexal lesions using photoacoustic imaging to improve sonographic O-RADS risk assessment.
    Zhu Q; Luo H; Middleton WD; Itani M; Hagemann IS; Hagemann AR; Hoegger MJ; Thaker PH; Kuroki LM; McCourt CK; Mutch DG; Powell MA; Siegel CL
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):891-903. PubMed ID: 37606287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX: a Portuguese multicenter study.
    Borges AL; Brito M; Ambrósio P; Condeço R; Pinto P; Ambrósio B; Mahomed F; Gama JMR; Bernardo MJ; Gouveia AI; Djokovic D
    Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of the Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United States.
    Jha P; Gupta A; Baran TM; Maturen KE; Patel-Lippmann K; Zafar HM; Kamaya A; Antil N; Barroilhet L; Sadowski EA
    JAMA Netw Open; 2022 Jun; 5(6):e2216370. PubMed ID: 35679042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective comparative trial comparing O-RADS, IOTA ADNEX model, and RMI score for preoperative evaluation of adnexal masses for prediction of ovarian cancer.
    Poonyakanok V; Tanmahasamut P; Jaishuen A
    J Obstet Gynaecol Res; 2023 May; 49(5):1412-1417. PubMed ID: 36895122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.